About: Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review
Creator	Johnson, S Joseph, J Fajgenbaum, David Madison, S Alexander, Beschloss Anne, Taylor Casey, J Duncan, Mackay Erin, Napier Go, Gorzewski, Joanna, Jiang Kakkis, Khor, Kim, Ruth-Anne Langan, Pai Laura Hernandez-Miyares, Mark-Avery, Tamakloe Mccarthy, Mileva, Repasky Philip, Angelides Pierson, Powers, Rozena, Rasheed Sarah, Frankl Sheila, K Vivek, Nimgaonkar
Source	Medline; PMC
abstract	The emergence of SARS-CoV-2/2019 novel coronavirus (COVID-19) has created a global pandemic with no approved treatments or vaccines. Many treatments have already been administered to COVID-19 patients but have not been systematically evaluated. We performed a systematic literature review to identify all treatments reported to be administered to COVID-19 patients and to assess time to clinically meaningful response for treatments with sufficient data. We searched PubMed, BioRxiv, MedRxiv, and ChinaXiv for articles reporting treatments for COVID-19 patients published between 1 December 2019 and 27 March 2020. Data were analyzed descriptively. Of the 2706 articles identified, 155 studies met the inclusion criteria, comprising 9152 patients. The cohort was 45.4% female and 98.3% hospitalized, and mean (SD) age was 44.4 years (SD 21.0). The most frequently administered drug classes were antivirals, antibiotics, and corticosteroids, and of the 115 reported drugs, the most frequently administered was combination lopinavir/ritonavir, which was associated with a time to clinically meaningful response (complete symptom resolution or hospital discharge) of 11.7 (1.09) days. There were insufficient data to compare across treatments. Many treatments have been administered to the first 9152 reported cases of COVID-19. These data serve as the basis for an open-source registry of all reported treatments given to COVID-19 patients at www.CDCN.org/CORONA. Further work is needed to prioritize drugs for investigation in well-controlled clinical trials and treatment protocols. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40121-020-00303-8) contains supplementary material, which is available to authorized users.
has issue date	2020-05-27(xsd:dateTime)
bibo:doi	10.1007/s40121-020-00303-8
bibo:pmid	32462545
has license	no-cc
sha1sum (hex)	ea569ee1e74e0b5b38dc1c9ee783be6e82586366
schema:url	https://doi.org/10.1007/s40121-020-00303-8
resource representing a document's title	Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review
has PubMed Central identifier	PMC7251321
has PubMed identifier	32462545
schema:publication	Infect Dis Ther
resource representing a document's body	covid:ea569ee1e74e0b5b38dc1c9ee783be6e82586366#body_text
is schema:about of	named entity 'Systematic' named entity 'Cases' named entity 'Systematic Review' named entity 'intravenous immunoglobulin' named entity 'case fatality rate' named entity 'non-specific' named entity 'ACE2 receptor' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'randomized controlled trials' named entity 'moxifloxacin' named entity 'case series' named entity 'China' named entity 'lopinavir/ritonavir' named entity 'medical care' named entity 'clinically meaningful' named entity 'ACE2 receptor' named entity 'vasopressors' named entity 'Creative Commons' named entity 'COVID-19' named entity 'CART' named entity 'public health' named entity 'umifenovir' named entity 'Hydroxychloroquine' named entity 'inpatient care' named entity 'analyzed data' named entity 'hypothesis tests' named entity 'endosomal' named entity 'COVID' named entity 'randomized controlled trial' named entity 'randomized controlled trials' named entity 'corticosteroids' named entity 'peer-review' named entity 'randomized controlled trial' named entity 'data quality' named entity 'quality standards' named entity 'influenza' named entity 'anti-viral' named entity 'publication bias' named entity 'COVID-19' named entity 'C-reactive protein' named entity 'clinical trial' named entity 'make decisions' named entity 'convalescent plasma' named entity 'randomized controlled trial' named entity 'cytokine storm' named entity 'critically ill patients' named entity 'influenza infection' named entity 'chimeric antigen receptor T cell' named entity 'COVID' named entity 'medical care' named entity 'azithromycin' named entity 'umifenovir' named entity 'COVID19' named entity 'Umifenovir'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software